Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Antengene, Ascentage, Biontech, Incannex Healthcare, Janssen-Cilag, LG Chem Life Sciences, Mesoblast, Moderna, Neuren, Pfizer, Regent Pacific, Rhizen, Shanghai Junshi, Telix, Transthera, Wanbang, Yiling.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Ampio, Apeiron, Appili, Ascletis, Astrazeneca, Beigene, Celularity, Dr. Reddy’s, Enlivex, Inovio, Junshi, Neurorx, Puretech Health, Relief, Senhwa, Sichuan Clover, Takeda, Therapeutics Solution, Zymeworks. Extra

Biopharmas in Asia-Pacific raising money in public or private financings, including: Auris Medical, Burning Rock, Canbridge, ILC, I-Mab, Neuroglee, Olix, Perseus Proteomics, Sinovac, Sunshine.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: 3D Medicines, Astellas, Astrazeneca, Aurigene Discovery Technologies, Auris Medical, Beigene, Biohaven, Cel-Sci, Eli Lilly, Exelixis, Eyam Vaccines and Immunotherapeutics, Fusion Antibodies, Genscript Probio, Grünenthal, Helsinn, Horizon Discovery, I-Mab, Initium, Inovio, Kalivir Immunotherapeutics, Kaneka Eurogentec, Kyowa Kirin, Luca Science, Memo, Moderna, Nabriva, Oncolys, Pharmaengine, Qilu, Qualigen, Regent Pacific, Rosetta, Sanyou, Sellas Life Sciences, Sentinel Oncology, Seqirus, Sesen, Shanghai Fosun, Sherlock, Sinovant Sciences, Sosei, Tetra, Tolo, Transposon, Tubulis, Vigeneron, Wuxi Apptec, Wuxi Biologics, Zymeworks.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Adagene.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amgen, Beigene, Cerecor, Cyxone, Henlius, ITM, Ix, Takeda, Turning Point.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alnylam, Astrazeneca, Athira, Betterlife, Boehringer Ingelheim, Bristol Myers Squibb, Centogene, Checkmate, Chinook, Ciloa, Citius, CN Pharm, Eyepoint, Genprex, Havn, Hyundai Bioscience, Inventiva, Kubota, Lineage Cell, Merck, Mannkind, Mind Cure, Neuraxpharm, Novecite, Pascal, Qrumpharma, Recce, Secarna, Soligenix, Sunshine, Theratechnologies, Transcend, Tris, Virpax, Xencor.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aldeyra, Altimmune, Arena, Astrazeneca, Axsome, Bellus, Cardior, Curis, Domain, Harpoon, Larimar, Monopar, Novaliq, Panbela, Sojournix, Vicore, Xenon.

Biopharmas raising money in public or private financings, including: Achieve, Alx, Amryt, Arcturus, Ibio, IGM, Kinnate, Kura, Marinus, Nuance, Progenity, Regulus, Repligen, Scineuro, Sutro, Syndax, Vigil.

New hires and promotions in the biopharma industry, including: Avid, Candel, Cerevance, Delcath, Kronos, Opiant, Protara, Seranovo, Tufts Center.